Modified hvi-type hirudin and process for the manufacture thereof
CA 2018211 C · Owner: Honjo, Masaru · Inventors: Honjo, Masaru; Hori, Michiko; Ando, Kazunori
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Modified HV1 -type hirudin in which valine at the N-terminal end of the HV1-type hirudin and aspartic acid at the 5th residue of the N-terminal end were replaced with alanine and glutamic acid, respectively. A secretion plasmid into which a DNA sequence coding for a precursor with an addition of a secretion signal of neutral protease of Bacillus amyloliquifacience at the N-terminal end of this modified HV1-type hirudin is integrated is introduced into bacteria of the genus Bacillus and the precursor is expressed intracellularly. The modified HV1-type hirudin can be efficiently secreted extracellularly while maintaining its high thrombin inhibiting activity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 4, 1990 and granted February 20, 1996. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 4, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 4, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.